Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 1c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts XERS Hot Sheet
Join SI Premium – FREE
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of $0.01, $0.01 better than the analyst estimate of $0.00. Revenue for the quarter came in at $83.13 million versus the consensus estimate of $83.7 million.
GUIDANCE:
Xeris Pharmaceuticals Inc. sees FY2026 revenue of $380-390 million, versus the consensus of $383.3 million.
For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Fidelity National Information Services, Inc. (FIS) Tops Q3 EPS by 1c ; Offers Guidance
- Medline Inc. (MDLN) Reports Q3 EPS of $0.44
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
